James V. Cassella

CIK: 0001353528

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

TRVI

Trevi Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (3 total)

TRVI
Trevi Therapeutics, Inc.
Feb 19, 2026
Award(A)
Stock Option (right to buy)
Direct
215K shares-
TRVI
Trevi Therapeutics, Inc.
Feb 18, 2025
Award(A)
Stock Option (right to buy)
Direct
257.5K shares-
TRVI
Trevi Therapeutics, Inc.
Sep 30, 2024
Award(A)
Stock Option (right to buy)
Direct
400K shares-

		Type	Shares	Price		Ownership
Feb 19, 2026	TRVI Trevi Therapeutics, Inc.	Award(A) Stock Option (right to buy)	215,000	-	-	Direct
Feb 18, 2025	TRVI Trevi Therapeutics, Inc.	Award(A) Stock Option (right to buy)	257,500	-	-	Direct
Sep 30, 2024	TRVI Trevi Therapeutics, Inc.	Award(A) Stock Option (right to buy)	400,000	-	-	Direct

1-3 of 3 transactions

About Cassella James V

Cassella James V (SEC CIK 0001353528) files insider reports with the SEC as Chief Development Officer of Trevi Therapeutics, Inc. (TRVI).

Signal8 holds 3 ownership filings by Cassella James V, all Form 4s, filed between Oct 1, 2024 and Feb 20, 2026. Those filings report 3 transactions, from Sep 30, 2024 to Feb 19, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Cassella James V's filings is in NEW HAVEN, CT.

Recent filings by Cassella James V

Feb 19, 2026: Grant or award of TRVI derivative securities (Form 4, code A).
Feb 18, 2025: Grant or award of TRVI derivative securities (Form 4, code A).
Sep 30, 2024: Grant or award of TRVI derivative securities (Form 4, code A).

Other insiders filing for Trevi Therapeutics, Inc. (TRVI)

How to read Form 4 transaction codes